141 related articles for article (PubMed ID: 37717306)
1. Tumefactive demyelinating lesions versus CNS neoplasms, a comparative study.
Chew SH; Achmad Sankala HB; Chew E; Md Arif MHB; Mohd Zain NR; Hashim H; Koya Kutty SB; Chee YC; Mohd Saleh NB; Ong BH; Viswanathan S
Mult Scler Relat Disord; 2023 Nov; 79():104992. PubMed ID: 37717306
[TBL] [Abstract][Full Text] [Related]
2. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms.
Mabray MC; Cohen BA; Villanueva-Meyer JE; Valles FE; Barajas RF; Rubenstein JL; Cha S
AJR Am J Roentgenol; 2015 Nov; 205(5):1075-85. PubMed ID: 26496556
[TBL] [Abstract][Full Text] [Related]
3. Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging.
Kim DS; Na DG; Kim KH; Kim JH; Kim E; Yun BL; Chang KH
Radiology; 2009 May; 251(2):467-75. PubMed ID: 19261924
[TBL] [Abstract][Full Text] [Related]
4. Tumefactive multiple sclerosis versus high grade glioma: A diagnostic dilemma.
French H; Fontes-Villalba A; Maharaj M; Naidoo CSY; Bhatia K; Paterson A; Cook R; Parratt J
Surg Neurol Int; 2022; 13():146. PubMed ID: 35509579
[TBL] [Abstract][Full Text] [Related]
5. Tumefactive multiple sclerosis versus high-grade glioma: A diagnostic dilemma.
French HD
Surg Neurol Int; 2021; 12():199. PubMed ID: 34084626
[TBL] [Abstract][Full Text] [Related]
6. Differentiating between Central Nervous System Lymphoma and High-grade Glioma Using Dynamic Susceptibility Contrast and Dynamic Contrast-enhanced MR Imaging with Histogram Analysis.
Murayama K; Nishiyama Y; Hirose Y; Abe M; Ohyu S; Ninomiya A; Fukuba T; Katada K; Toyama H
Magn Reson Med Sci; 2018 Jan; 17(1):42-49. PubMed ID: 28515410
[TBL] [Abstract][Full Text] [Related]
7. Tumefactive demyelinating lesions: A comprehensive review.
Algahtani H; Shirah B; Alassiri A
Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436
[TBL] [Abstract][Full Text] [Related]
8. Proton magnetic resonance spectroscopy differentiates tumefactive demyelinating lesions from gliomas.
Ikeguchi R; Shimizu Y; Abe K; Shimizu S; Maruyama T; Nitta M; Abe K; Kawamata T; Kitagawa K
Mult Scler Relat Disord; 2018 Nov; 26():77-84. PubMed ID: 30237108
[TBL] [Abstract][Full Text] [Related]
9. Clinicoradiologic features distinguish tumefactive multiple sclerosis from CNS neoplasms.
Lin X; Yu WY; Liauw L; Chander RJ; Soon WE; Lee HY; Tan K
Neurol Clin Pract; 2017 Feb; 7(1):53-64. PubMed ID: 29849229
[TBL] [Abstract][Full Text] [Related]
10. Differential diagnosis of central lymphoma and high-grade glioma: dynamic contrast-enhanced histogram.
Zhang HW; Lyu GW; He WJ; Lei Y; Lin F; Feng YN; Wang MZ
Acta Radiol; 2020 Sep; 61(9):1221-1227. PubMed ID: 31902220
[TBL] [Abstract][Full Text] [Related]
11. Tumefactive demyelinating lesions: a retrospective cohort study in Thailand.
Ongphichetmetha T; Aungsumart S; Siritho S; Apiwattanakul M; Tanboon J; Rattanathamsakul N; Prayoonwiwat N; Jitprapaikulsan J
Sci Rep; 2024 Jan; 14(1):1426. PubMed ID: 38228919
[TBL] [Abstract][Full Text] [Related]
12. Neuroimaging and clinicopathological differences between tumefactive demyelinating lesions and sentinel lesions of primary central nervous system lymphoma.
Sun C; Han J; Lin Y; Qi X; Li C; Liu J; Qiu F
Front Immunol; 2022; 13():986473. PubMed ID: 36059526
[TBL] [Abstract][Full Text] [Related]
13. Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions.
Tremblay MA; Villanueva-Meyer JE; Cha S; Tihan T; Gelfand JM
J Neurol Sci; 2017 Oct; 381():83-87. PubMed ID: 28991721
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of tumefactive demyelinating lesions and glioma by clinical presentations and neuroimaging studies].
Liu J; Qiao W; Zheng K; Zhao H; Qian H; Yao S; Duan F; Qiu F; Qi X
Zhonghua Yi Xue Za Zhi; 2014 Oct; 94(39):3047-51. PubMed ID: 25549675
[TBL] [Abstract][Full Text] [Related]
15. Combining Diffusion Tensor Metrics and DSC Perfusion Imaging: Can It Improve the Diagnostic Accuracy in Differentiating Tumefactive Demyelination from High-Grade Glioma?
Hiremath SB; Muraleedharan A; Kumar S; Nagesh C; Kesavadas C; Abraham M; Kapilamoorthy TR; Thomas B
AJNR Am J Neuroradiol; 2017 Apr; 38(4):685-690. PubMed ID: 28209583
[TBL] [Abstract][Full Text] [Related]
16. Utility of proton MR spectroscopy for differentiating typical and atypical primary central nervous system lymphomas from tumefactive demyelinating lesions.
Lu SS; Kim SJ; Kim HS; Choi CG; Lim YM; Kim EJ; Kim DY; Cho SH
AJNR Am J Neuroradiol; 2014 Feb; 35(2):270-7. PubMed ID: 23928144
[TBL] [Abstract][Full Text] [Related]
17. Histogram analysis of apparent diffusion coefficient maps for differentiating primary CNS lymphomas from tumefactive demyelinating lesions.
Lu SS; Kim SJ; Kim N; Kim HS; Choi CG; Lim YM
AJR Am J Roentgenol; 2015 Apr; 204(4):827-34. PubMed ID: 25794073
[TBL] [Abstract][Full Text] [Related]
18. MRI Findings in Tumefactive Demyelinating Lesions: A Systematic Review and Meta-Analysis.
Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
AJNR Am J Neuroradiol; 2018 Sep; 39(9):1643-1649. PubMed ID: 30115676
[TBL] [Abstract][Full Text] [Related]
19. Tumefactive Demyelinating Lesions and Pregnancy.
Plantone D; Piantadosi C; Ruggieri S; Anelli V; Koudriavtseva T
Neurol India; 2019; 67(6):1519-1521. PubMed ID: 31857550
[TBL] [Abstract][Full Text] [Related]
20. Differentiation of tumefactive demyelinating lesions from high-grade gliomas with the use of diffusion tensor imaging.
Toh CH; Wei KC; Ng SH; Wan YL; Castillo M; Lin CP
AJNR Am J Neuroradiol; 2012 May; 33(5):846-51. PubMed ID: 22173757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
